Evaluation of the CRISPR/Cas9 system as genome editing platform for the Mucopolysaccharidosis IV A using a strategy for induction of higher homologous recombination frequency. Univ. Sci. 2025;30:82-106. doi:10.11144/Javeriana.SC30.eotc